Undesirable patient outcomes
During EGFR-TKI treatment, of the total 232 older advanced NSCLC patients, 72 (31.0%) experienced >=grade 3 EGFR-TKI-related AEs, of which 30 (41.7%) patients experienced liver function–related AEs (e.g., elevated transaminase), 23 (31.9%) patients experienced skin-related AEs (e.g., rash, paronychia), and 12 (16.7%) patients experienced gastrointestinal AEs (e.g., diarrhea, nausea, loss of appetite). In addition, 5 patients experienced >=grade 3 pneumonitis, Of the total 232 patients, 86 (37.1%) had at least one unexpected hospitalization and 21 (17.2%) patients had two or more hospitalizations. In addition,40 (17.2%) patients were hospitalized because of exacerbation of NSCLC, 23 (9.9%) because of EGFR-TKI-related AEs, and 37 (16.0%) because of complications unrelated to NSCLC or EGFR-TKI-related AEs.
Undesirable outcomes in PP(+) and PP(–) older advanced NSCLC